Abstracts tagged "clinical trials"

Abstract Number: 702 • 2013 ACR/ARHP Annual Meeting
Prediction Of Worsening Of Skin Fibrosis In Patients With Diffuse Systemic Sclerosis Using The EULAR Scleroderma Trials and Research (EUSTAR) Registry
Britta Maurer¹, Nicole Graf², Beat A. Michel³, Carola Metzig⁴, Vivian Lanius⁴, Dinesh Khanna⁵ and Oliver Distler¹, ¹Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²graf biostatistics, Winterthur, Switzerland, ³Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁴Bayer Pharma AG, Berlin, Germany, ⁵University of Michigan Health System, Ann Arbor, MI
Background/Purpose: To identify predictive parameters for the progression of skin fibrosis in patients with diffuse cutaneous SSc (dcSSc) to enable 1) risk-stratification in clinical practice…
Abstract Number: 281 • 2013 ACR/ARHP Annual Meeting
GO-Kids Imaging Substudy: MRI Treatment Response To 30 Mg/m² 4-Weekly Subcutaneous injections Of Golimumab In Children With Polyarticular JIA – Preliminary Results Of The Open Label Portion
Nikolay Tzaribachev¹, Catrin Tzaribachev¹ and Bernd Koos², ¹Pediatric Rheumatology, PRI - Pediatric Rheumatology Research Institute, Bad Bramstedt, Germany, ²Clinic of Orthodontics, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany
GO-KIDS Imaging Substudy: MRI treatment response to 30 mg/m2 4-weekly subcutaneous injections of Golimumab in children with polyarticular JIA– preliminary results of the open label…
Abstract Number: 278 • 2013 ACR/ARHP Annual Meeting
Results Of a 24 Month Extension Study In Patients Who Participated In The Trial Of Early Aggressive Therapy In Polyarticular Juvenile Idiopathic Arthritis
Carol A. Wallace¹, John Bonsack², Steven J. Spalding³, Hermine Brunner⁴, Kathleen M. O'Neil⁵, Diana Milojevic⁶, Sarah Ringold⁷, Laura E. Schanberg⁸, Gloria C. Higgins⁹, Beth S. Gottlieb¹⁰, Joyce J. Hsu¹¹, Marilynn G. Punaro¹², Yukiko Kimura¹³ and Audrey F. Hendrickson¹⁴, ¹University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ²Pediatrics, University of Utah Health Sciences Center, Salt Lake City, UT, ³Pediatric Institute, Department of Pediatric Rheumatology, The Cleveland Clinic, Cleveland, OH, ⁴Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Pediatric Rheumatology, Riley Hospital for Children, Indianapolis, IN, ⁶Dept of Pediatric Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷Pediatrics, Seattle Children's Hospital/Univ of Washington, Seattle, WA, ⁸Pediatrics, Duke University Medical Center, Durham, NC, ⁹Pediatric Rheumatology Ohio State University, Nationwide Childrens Hosp, Columbus, OH, ¹⁰Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ¹¹Pediatric Rheumatology, Stanford University, Palo Alto, CA, ¹²Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ¹³Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ¹⁴Rheumatology, Seattle Children's Research Institute, Seattle, WA
Background/Purpose: The Trial of Early Aggressive Therapy in Polyarticular Juvenile Idiopathic Arthritis (TREAT-JIA) was a double-blind, randomized, placebo-controlled trial in 85 patients with onset of…
Abstract Number: 2830 • 2013 ACR/ARHP Annual Meeting
First Stage Of a Simon’s Two-Stage Optimal Approach Supports Placental Transfer Of Hydroxychloroquine and a Reduced Recurrence Rate Of The Cardiac Manifestations Of Neonatal Lupus
Peter M. Izmirly¹, Nathalie Costedoat-Chalumeau², Amit Saxena³, Amanda Zink⁴, Zoey Smith³, Deborah Friedman⁵ and Jill P. Buyon¹, ¹Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ²Internal Medicine, Hopital Cochin, Paris, France, ³Rheumatology, New York University School of Medicine, New York, NY, ⁴NYU Hospital for Joint Diseases, New York University School of Medicine, New York, NY, ⁵Division of Pediatric Cardiology, New York Medical College, Valhalla, NY
Background/Purpose: A previous case control study suggested that hydroxychloroquine (HCQ) might prevent the development of cardiac Neonatal Lupus (cardiac NL) in anti-SSA/Ro antibody (ab) exposed…
Abstract Number: L6 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety of Pregabalin in Patients with Fibromyalgia and Co-Morbid Depression Receiving Concurrent Antidepressant Therapy: A Randomized, 2-Way Crossover, Double-Blind, Placebo-Controlled Study
Lesley M. Arnold¹, Piercarlo Sarzi-Puttini², Pierre Arsenault³, Tahira Khan⁴, Pritha Bhadra Brown⁵, Andrew Clair⁵, Joseph Driscoll⁴, Jaren Landen⁴ and Lynne Pauer⁴, ¹Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, ²Azienda Ospedaliera Polo Universitario L. Sacco, Milano, Italy, ³Département de Médecine de Famille, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY
Background/Purpose: Fibromyalgia (FM) is characterized by chronic widespread pain and often associated with mood disorders including depression. Approximately 50–70% of FM patients have a lifetime…
Abstract Number: 2765 • 2013 ACR/ARHP Annual Meeting
A Double-Blind Randomized Placebo-Controlled Trial Of Lovastatin in Patients with Rheumatoid Arthritis
Cynthia Aranow¹, John J. Cush², Marcy B. Bolster³, Christopher C. Striebich⁴, Maria Dall'era⁵, Meggan Mackay⁶, Ewa Olech⁷, Tracy M. Frech⁸, J. Box⁹, Richard M. Keating¹⁰, Mary Chester M. Wasko¹¹, E. William St Clair¹², Alan Kivitz¹³, Betty Diamond¹⁴, Anne Davidson¹⁵, Meagan Spychala¹⁶, Ellen A. Goldmuntz¹⁷ and Autoimmunity Centers of Excellence¹⁸, ¹Feinstein Institute for Medical Research, Manhasset, NY, ²Baylor Research Institute and Baylor University Medical Center, Dallas, TX, ³Medicine, Medical University of South Carolina, Charleston, SC, ⁴University of Colorado Denver, Aurora, CO, ⁵Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁶Autoimmune & Musculoskeletal Disease, Feinstein Institute for Medical Research, Manhasset, NY, ⁷Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Internal Medicine-Division of Rheumatology, University of Utah School of Medicine, SLC, UT, ⁹Carolina Bone and Joint, Charlotte, NC, ¹⁰Rheumatology Section, The University of Chicago, Chicago, IL, ¹¹West Penn Allegheny Health System, Temple University School of Medicine, Pittsburgh, PA, ¹²Medicine, Duke Unversity Medical Center, Durham, NC, ¹³Altoona Center for Clinical Research, Duncansville, PA, ¹⁴Autoimmune & Musculoskeletal, Feinstein Institute for Medical Research, Manhasset, NY, ¹⁵Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY, ¹⁶Rho, Inc., Chapel Hill, NC, ¹⁷DAIT, NIAID/NIH, Bethesda, MD, ¹⁸NIAID, National Institutes of Health, Bethesda, MD
Background/Purpose: HMG -CoA reductase inhibitors (statins) are standard treatment for hyperlipidemia. In addition to lipid lowering abilities, statins exhibit multiple anti-inflammatory effects. The objectives of…
Abstract Number: 2675 • 2013 ACR/ARHP Annual Meeting
Phase 2 Trial On Triptorelin For Ovary Protection In Childhood-Onset Systemic Lupus Erythematosus
Rina Mina¹, Andreas Reiff², Clovis A. Silva³, Patricia Vega Fernandez⁴, Gloria C. Higgins⁵, Lisa F. Imundo⁶, Marisa S. Klein-Gitelman⁷, Calvin Williams⁸, Carol A. Wallace⁹, Nadia E. Aikawa¹⁰, Shannen L. Nelson¹¹, Jun Ying¹², Susan R. Rose¹³ and Hermine Brunner¹⁴, ¹Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, ³Children's Institute, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁴Cincinnati Children's Hospital Medica Center, CINCINNATI, OH, ⁵Pediatric Rheumatology Ohio State University, Nationwide Childrens Hosp, Columbus, OH, ⁶Pediatric and Adult Rheumatology Columbia University Medical Center, New York, NY, ⁷Division of Rheumatology, Children's Memorial Hospital, Chicago, IL, ⁸Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, ⁹University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ¹⁰Reumatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ¹¹Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹²Medicine-Internal Medicine-General Medicine, University of Cincinnati, Cincinnati, OH, ¹³Endocrinology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁴PRCSG, Cincinnati, OH
Background/Purpose: Gonadotoxicity is a known side effect of cyclophosphamide (CYC) therapy in childhood-onset systemic lupus erythematosus (cSLE). Gonadotropin releasing hormone (GnRH) agonists, such as triptorelin,…
Abstract Number: 2392 • 2013 ACR/ARHP Annual Meeting
Impact Of CT-P13 and Originator Infliximab Treatment On Quality Of Life Derived From The Health Assessment Questionnaire (HAQ) and Short-Form 36 (SF-36) From a Randomized, Double-Blind Trial In Patients With Active RA
Dae-Hyun Yoo¹, Andriy Yagensky², Antoaneta Toncheva³, Osca Ruiz Santacruz⁴, Fidencio Cons Molina⁵, Yunju Bae⁶, Taek Kwon⁶, SinHye Kim⁶, Peter Lacouture⁷, Teresa Kok⁸ and Won Park⁹, ¹Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Lutsk City Hospital, Lutsk, Ukraine, ³National Multiprofile Transport Hospital, Sofia, Bulgaria, ⁴Centro Integral de Reumatología e Inmunología - CIREI S.A.S, Bogotá, Colombia, ⁵Centro de Investigacion en Artritis y Osteoporosis, Mexicali, Mexico, ⁶Celltrion Inc., Incheon, South Korea, ⁷Hospira Inc, Lake forest, IL, ⁸Hospira Inc., Lake Forest, IL, ⁹Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea
Background/Purpose: Quality of life and functionality are important outcome metrics in understanding the value of therapeutic interventions in RA. Biological products have become an established…
Abstract Number: 2355 • 2013 ACR/ARHP Annual Meeting
Sarilumab, a Subcutaneously-Administered, Fully-Human Monoclonal Antibody Against The IL-6 Receptor Alpha: Using Acute Phase Reactants, Efficacy and Safety Parameters To Inform Phase 3 Dose Selection
Janet van Adelsberg¹, Steven P. Weinstein², Neil Graham³, Tanya Momtahen⁴, Chunpeng Fan⁵ and Stefano Fiore⁶, ¹Clinical Science, Regeneron Pharmaceutials, Inc., Tarrytown, NY, ²Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ³Program Direction, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Program Direction, Sanofi, Bridgewater, NJ, ⁵Biostatistics, Sanofi, Bridgewater, NJ, ⁶Clinical Science, Sanofi, Bridgewater, NJ
Background/Purpose: Sarilumab (SAR) is a fully human mAb directed against IL-6Rα. In phase 2 MOBILITY Part A (NCT01061736), SAR administered SC plus MTX (methotrexate 10-25…
Abstract Number: 2258 • 2013 ACR/ARHP Annual Meeting
Less Than 5% Of Ethnic Minority Rheumatoid Arthritis Patients Meet Inclusion Criteria For Randomized Controlled Clinical Trials
Gail S. Kerr¹, Yusuf Yazici², Christopher Swearingen³, Chunqiao Luo⁴, Yvonne R. S. Sherrer⁵, Edward L. Treadwell⁶, Angelia D. Mosley-Williams⁷, Luis R. Espinoza⁸, Rodolfo Perez Alamino⁹, Sharon Dowell¹⁰, Ignacio Garcia-Vallardes¹¹, Theresa Lawrence-Ford¹², Adrian Godoy¹⁰, Akgun Ince¹³ and Cindy Flower¹⁴, ¹Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ²New York University Hospital for Joint Diseases, New York, NY, ³Pediatrics and Biostatistics, University of Arkansas for Medical Sciences, Little Rock, AR, ⁴Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, ⁵Rheum/Immunology, Centre Rheum Immunol Arthritis, Fort Lauderdale, FL, ⁶Dept Medicine Div of Rheum, East Carolina University, Greenville, NC, ⁷John Dingell VAMC, Detroit, MI, ⁸Medicine-Section of Rheum, LSU Medical Center, New Orleans, LA, ⁹Rheumatology, Lousiana State University and LSU Medical Center, New Orleans, LA, ¹⁰Division of Rheumatology, Howard University, Washington, DC, ¹¹Rheumatology Clinical Practice, Guadalajara, Gaudalajara, Mexico, ¹²North Georgia Rheumatology Group, PC, Lawrenceville, GA, ¹³Arthitis Consultants Inc, Saint Louis University, St. Louis, MO, ¹⁴Medicine, University of the West Indies, Bridgetown, Barbados
Background/Purpose: RCT are the gold standard for therapeutic efficacy, yet many studies indicate most patients seen in routine clinical care do not meet inclusion criteria.…
Abstract Number: 1809 • 2013 ACR/ARHP Annual Meeting
Topline Results Of The Biomarkers Of Lupus Disease (BOLD) Study: Clinical and Mechanistic Perplexities Of Lupus Treatment Trials Can Be Mitigated By Eliminating Background Immune Suppressants
Joan T. Merrill¹, Frederick W. Immermann², Tianhui Zhou³, Margot O'Toole⁴, Maryann Whitley⁵, Andrew A. Hill⁵, Ying Zhang⁵, David von Schack⁵, Padmalatha S. Reddy⁵, Jaime L. Masferrer⁴, Stan Kamp¹, Joel M. Guthridge⁶, Aikaterini Thanou⁷, Paul Wu⁵, Theresa Paradis⁵, William M. Mounts⁵, Judith A. James⁸ and Sudhakar T. Sridharan², ¹Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²BioTherapeutics R&D, Pfizer Inc, Collegeville, PA, ³BioTherapeutics R&D, Bristol Myers Squibb, Princeton, NJ, ⁴independent consultant, Cambridge, MA, ⁵Pfizer Inc, Cambridge, MA, ⁶Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Arthritis and Clinical Immmunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁸Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The BOLD study was designed to test the discriminatory capacity and safety of a trial design eliminating background immune suppressants (IS) in SLE patients…
Abstract Number: 1780 • 2013 ACR/ARHP Annual Meeting
The Randomized Placebo Phase Study of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis
Norman T. Ilowite¹, Kristi Prather², Yuliya Lokhnygina³, Laura E. Schanberg⁴, Melissa Elder⁵, Diana Milojevic⁶, James W. Verbsky⁷, Steven J. Spalding⁸, Yukiko Kimura⁹, Lisa F. Imundo¹⁰, Marilynn G. Punaro¹¹, David D. Sherry¹², Stacey E. Tarvin¹³, Lawrence S. Zemel¹⁴, James D. Birmingham¹⁵, Beth S. Gottlieb¹⁶, Michael L. Miller¹⁷, Kathleen M. O'Neil¹⁸, Natasha M. Ruth¹⁹, Carol A. Wallace²⁰, Nora G. Singer²¹ and Christy I. Sandborg²², ¹Pediatrics, The Children's Hospital at Montefiore, Bronx, NY, ²Statistics, Duke Clinical Research Institute, Durham, NC, ³Duke Clinical Research Institute, Durham, NC, ⁴Pediatrics, Duke University Medical Center, Durham, NC, ⁵Pediatrics, University of Florida, Gainesville, HI, ⁶Dept of Pediatric Rheumatology, University of California, San Francisco, San Francisco, CA, ⁷Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, ⁸Pediatric Institute, Department of Pediatric Rheumatology, The Cleveland Clinic, Cleveland, OH, ⁹Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ¹⁰Pediatric and Adult Rheumatology Columbia University Medical Center, New York, NY, ¹¹Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ¹²Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ¹³Pediatric Rheumatology, Riley Hospital for Children, Indianapolis, IN, ¹⁴Pediatric Rheumatology Collaborative Study Group, Cincinnati, OH, ¹⁵Medicine & Pediatrics, Rheumatology, Michigan State University College of Human Medicine, Grand Rapids, MI, ¹⁶Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ¹⁷Rheumatology, Childrens Memorial Hospital, Chicago, IL, ¹⁸Division of Pediatric Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁹Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ²⁰University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ²¹Rheumatology, MetroHealth Medical Center, Cleveland, OH, ²²Pediatric Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: The RAndomized Placebo Phase Study Of Rilonacept in the Treatment of Systemic Juvenile Idiopathic Arthritis (RAPPORT) is a multicenter controlled trial using a…
Abstract Number: 1609 • 2013 ACR/ARHP Annual Meeting
AMG 811 (anti-IFN-gamma) Treatment Leads To a Reduction In The Whole Blood IFN-Signature and Serum CXCL10 In Subjects With Systemic Lupus Erythematosus: Results Of Two Phase I Studies
David A. Martin¹, Andrew Welcher², Michael Boedigheimer², Zahir Amoura³, Alan Kivitz⁴, Jill P. Buyon⁵, Jorge Sanchez-Guerrero⁶, Juanita Romero-Diaz⁷, Alla Rudinskaya⁸, Kevin M. Latinis⁹, S Cohen¹⁰, Cynthia Aranow¹¹, Mike Damore², Winnie Sohn², Kit Chiu², Christine Wang¹², Naren Chirmule², Barbara Sullivan² and James Chung², ¹Medical Sciences, Amgen, Seattle, WA, ²Amgen, Thousand Oaks, CA, ³Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ⁶UHN Toronto Western Hospital, Toronto, ON, Canada, ⁷Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁸Danbury Hospital, Danbury, CT, ⁹Latinis Rheumatology, Leawood, KS, ¹⁰Metroplex Clinical Research Center, Dallas, TX, ¹¹The Feinstein Institute, Manhasset, NY, ¹²Biostatistics, Amgen, Thousand Oaks, CA
Background/Purpose: Interferon-gamma (IFN-g) is a major pro-inflammatory cytokine that modulates the function of several important populations of immune cells including B cells, T cells, and…
Abstract Number: 1857 • 2012 ACR/ARHP Annual Meeting
Identifying Core Symptom Domains in the Fibromyalgia Impact Questionnaire: Principal Component Analysis of Data From Milnacipran Clinical Studies
Philip J. Mease¹, Robert M. Bennett², Robert H. Palmer³ and Yong Wang⁴, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Medicine & Nursing, Oregon Health & Science Univ, Portland, OR, ³Forest Research Institute, Inc., Jersey City, NJ, ⁴Forest Research Institute, Jersey City, NJ
Background/Purpose: The Fibromyalgia Impact Questionnaire (FIQ) is a multidimensional instrument that encompasses many of the core domains recommended by OMERACT for evaluation in fibromyalgia (FM)…
Abstract Number: 755 • 2012 ACR/ARHP Annual Meeting
Sifalimumab, an Anti-IFN-Alpha Monoclonal Antibody Shows Target Suppression of a Type I IFN Signature in Blood and Muscle of Dermatomyositis and Polymyositis Patients
Brandon W. Higgs¹, Wei Zhu², Chris Morehouse¹, Wendy White³, Philip Brohawn¹, Charles Le⁴, Anthony A Amato⁵, David Fiorentino⁶, Steven A. Greenberg⁵, Laura Richman¹, Warren Greth⁴, Bahija Jallal¹ and Yihong Yao³, ¹Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ²Translational Science, MedImmune, LLC, Gaithersburg, MD, ³Translational Sciences, MedImmune, Gaithersburg, MD, ⁴Clinical Development, MedImmune, LLC, Gaithersburg, MD, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Dermatology, Stanford University School of Medicine, Redwood City, CA
Background/Purpose: To assess the pharmacodynamic effects of sifalimumab, an investigational anti-IFN-alpha monoclonal antibody, in the blood and muscle of adult dermatomyositis and polymyositis patients by…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].